Image may be NSFW.
Clik here to view.
Novocure (NSDQ:NVCR) touted today the final analysis of a pivotal Phase III trial that evaluated Optune combined with temozolomide in newly-diagnosed glioblastoma patients.
The analysis, published today in the Journal of the American Medical Association (JAMA), showed that Novocure’s Optune-temozolomide combo extended overall survival and progression-free survival by 37% compared to temozolomide alone.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Novocure’s Optune, drug combo adds months to the lives of GBM patients appeared first on MassDevice.
